Lanzhou Foci Pharmaceutical Co.Ltd(002644)
First quarter report 2021
Updated in March 2022
Section I important tips
The board of directors, the board of supervisors and the directors, supervisors and senior managers of the company guarantee that the contents of the quarterly report are true, accurate and complete without false records, misleading statements or major omissions, and bear individual and joint legal liabilities.
All directors have attended the board meeting to consider this quarterly report.
Shi Aiguo, the person in charge of the company, Yao Yilei, the person in charge of accounting, and Xu xiankai, the person in charge of the accounting organization (the person in charge of Accounting), declare that they guarantee the authenticity, accuracy and completeness of the financial statements in the quarterly report.
Section II basic information of the company
1、 Major accounting data and financial indicators does the company need to retroactively adjust or restate the accounting data of previous years □ yes √ no
Increase or decrease in the reporting period compared with the same period of the previous year
Operating income (yuan): 1774340872213796440924 28.61%
Net profit attributable to shareholders of listed company (yuan) 23105239341231423092 87.63%
Deduction of non recurring losses attributable to shareholders of listed companies
Profit net profit (yuan) 859216290721301236 19.12%
Net cash flow from operating activities (yuan) 29491155971388612413 112.38%
Basic earnings per share (yuan / share) 0.0452 0.026173.36%
Diluted earnings per share (yuan / share) 0.0452 0.026173.36%
Weighted average return on net assets 1.44%, 0.77%, 86.62%
Increase or decrease at the end of the reporting period compared with the end of the previous year
Total assets (yuan): 2419 Baoji Titanium Industry Co.Ltd(600456) 04226713250863 6.73%
Net assets attributable to shareholders of the listed company (yuan) 160519593926159115968797 0.88%
□ amount of non recurring items and inapplicability
Unit: Yuan
Description of project amount from the beginning of the year to the end of the reporting period
Government subsidies included in the current profits and losses (closely related to enterprise business, according to the national unified plan)
I. government subsidies (excluding standard quota or quota) 1704296946
Other non operating income and expenditure other than the above items 3123811
Less: income tax impact 256113114
Total 1457643–
For the non recurring profit and loss items defined by the company according to the definition of explanatory Announcement No. 1 on information disclosure of companies offering securities to the public – non recurring profit and loss, and the non recurring profit and loss items listed in explanatory Announcement No. 1 on information disclosure of companies offering securities to the public – non recurring profit and loss are defined as recurring profit and loss items, Explain the reasons □ applicable √ not applicable. During the reporting period, the company did not define the non recurring profit and loss items as recurring profit and loss items as defined and listed in the explanatory announcement on information disclosure of companies offering securities to the public No. 1 – non recurring profit and loss.
2、 Total number of shareholders and shareholding of top 10 shareholders at the end of the reporting period table 1 total number of ordinary shareholders and preferred shareholders with voting rights restored and shareholding of top 10 shareholders
Unit: shares
Total number of common shareholders at the end of the reporting period preferred shares with voting rights restored at the end of the reporting period
Total 32715 East (if any) 0
Shareholding of top 10 shareholders
Pledge or freezing of Holding Limited sales conditions
Shareholder name shareholder nature shareholding proportion shareholding number of shares
Number of shares in status
Pledge of state-owned legal person of Lanzhou Fuci pharmaceutical industry
Development Group Co., Ltd. 61.63% 31471367670000000
Jiangchuangcheng domestic natural person 0.60% 3076124
Gao Jianmin domestic natural person 0.57% 2915200
Zheng Muping natural person 0.51% 2 Shanghai Pudong Development Bank Co.Ltd(600000)
Zhang Hu natural person 0.49% 2480000
Natural persons in the army and Navy 0.43% 2201735
Luo Chengyuan domestic natural person 0.21% 1090000
Zhang Xuesong domestic natural person 0.21% 1061900
Zhang Guangming domestic natural person 0.20% 1000000
Zuo Suqin natural person 0.19% 991239
Shareholding of the top 10 shareholders with unlimited sales conditions
Types of shares
Name of shareholders and number of shares with unlimited sales conditions
Number of shares
Lanzhou Fuci Pharmaceutical Industry Development Group Co., Ltd. RMB common stock
Company 314713676
Jiang chuangcheng 3076124 ordinary shares
Gao Jianmin 2915200 ordinary shares
Zheng Muping 2 Shanghai Pudong Development Bank Co.Ltd(600000) ordinary shares
Zhang Hu 2480000 ordinary shares
Lu Haijun 2201735 ordinary shares
Luo Chengyuan 1090000 ordinary shares
Zhang Xuesong 1061900 ordinary shares
Zhang lighting 1000000 RMB ordinary shares
Zuo Suqin 991239 ordinary shares
Lanzhou Fuci Pharmaceutical Industry Development Group Co., Ltd., which is related to or acts in concert with the above shareholders, is the controlling shareholder of the company, and the company does not know the above other shareholders
Explain whether there is a related relationship between them, and it is unknown whether the above shareholders belong to the persons acting in concert specified in the measures for the administration of information disclosure of shareholding changes of shareholders of listed companies.
The top 10 shareholders participated in the margin trading business. Lanzhou Fuci Pharmaceutical Industry Development Group Co., Ltd. held Shanghai Pudong Development Bank Co.Ltd(600000) 00 shares through the investor’s credit account and 254713676 shares through the general information (if any) securities account.
Whether the top 10 ordinary shareholders and the top 10 ordinary shareholders with unlimited sales conditions of the company conducted agreed repurchase transactions during the reporting period □ yes √ no
